The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

By Ahmed Aboulenein and Maggie Fick WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and ...

"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...